Q2 2023 13F Holders as of 30 Jun 2023
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
36,995,063
-
Share change
-
+2,338,343
-
Total reported value
-
$380,309,728
-
Price per share
-
$10.28
-
Number of holders
-
76
-
Value change
-
+$26,266,207
-
Number of buys
-
53
-
Number of sells
-
13
Institutional Holders of ALPINE IMMUNE SCIENCES INC - COM (ALPN) as of Q2 2023
As of 30 Jun 2023,
ALPINE IMMUNE SCIENCES INC - COM (ALPN) was held by
76 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
36,995,063 shares.
The largest 10 holders included
RA CAPITAL MANAGEMENT, L.P., ORBIMED ADVISORS LLC, GREAT POINT PARTNERS LLC, Frazier Life Sciences Management, L.P., Lynx1 Capital Management LP, Paradigm Biocapital Advisors LP, BlackRock Inc., Omega Fund Management, LLC, VANGUARD GROUP INC, and COMMODORE CAPITAL LP.
This page lists
76
institutional shareholders reporting positions in this security
for the Q2 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.